You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):增資入股越光醫療暨獲得相關產品代理經銷權
格隆匯 03-24 19:00

格隆匯3月24日丨信立泰(002294.SZ)公佈,公司、公司子公司深圳市信立泰生物醫療工程有限公司(“生物醫療”)於近日與上海越光醫療科技有限公司(“越光醫療”)簽訂《產品經銷協議》,獲得越光醫療“動態心電記錄儀”、“房顫患教機”及新產品(包括但不限於前述產品的迭代升級產品及其他在研產品)在中國市場(即大陸、台灣地區、香港及澳門特別行政區,下同)二級及二級以上醫院終端的獨家經營權。在協議約定期限內,公司將根據銷售情況按一定比例支付越光醫療銷售提成。

同時,公司與越光醫療及其股東簽訂《增資協議》,以自有資金人民幣2009.1111萬元增資入股,獲得其9.43%股權。增資完成後,公司將持有越光醫療9.43%股權。

公司有關項目負責人將以同等估值,以自有資金人民幣122萬元增資入股,獲得越光醫療0.57%股權。

公司獲得相關產品的獨家代理經銷權後,有望憑藉在心腦血管領域的平台、渠道覆蓋能力,快速打開產品市場,獲得投資收益;同時將與桓晨Alpha Stent藥物洗脱冠脈支架錦江電子心電生理設備耗材公司在研的利伐沙班左心耳封堵器等形成產品醫療服務間的戰略協同,心腦血管患者提供疾病預防、篩查診斷藥物治療、手術治療、術後康復與慢病管理的全方位服務平台進一步提升公司在心腦血管領域綜合解決方案的優勢地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account